Lantern Pharma Inc (NAS:LTRN)
$ 3.27 -0.01 (-0.3%) Market Cap: 35.20 Mil Enterprise Value: 2.27 Mil PE Ratio: 0 PB Ratio: 1.14 GF Score: 39/100

Lantern Pharma Inc. Corporate Analyst Meeting Transcript

Sep 22, 2022 / 04:00PM GMT
Release Date Price: $4.75 (-3.06%)
Nicole Leber
Lantern Pharma Inc. - IR Associate, Finance & Administrative Coordinator

Good afternoon, everyone. I'm Nicole Leber with Investor Relations at Lantern Pharma, and welcome to Lantern's Childhood Cancer Awareness Month Key Opinion Leader Webinar. September is Childhood Cancer Awareness Month, a month dedicated to supporting, empowering and amplifying the voice of the childhood cancer community. According to the American Childhood Cancer Organization, childhood cancer is the #1 cause of death by disease for children in the United States with 1 out of 6 diagnosed children not surviving past 5 years of age. Additionally, despite advances in medicine, many childhood cancers remain incurable. As of 2020, only 6 new drugs have been developed to treat childhood cancers.

For today's KOL webinar, you'll be listening to Dr. Peter Houghton, who has dedicated his career to improving our understanding of pediatric cancers and to the development of therapies that will improve survival outcomes for childhood cancer patients. He is currently a professor and principal investigator at the Greehey

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot